

5th September 2018

Dear Editor

I would like to thank the referees for their comments related to this article and their support for the publication of the work.

The manuscript has been revised as follows:

1. Referee 00503486. Topical medicines may be of interest. The toxicities of retigabine and flupirtine make them bad choices for oral therapies.

Text has been added to the end of the section entitled Fibromyalgia with reference to the potential of the use of topical medicines as a therapeutic approach.

2. Referee 00504345. Many factors are involved in the pathogenesis of fibromyalgia, not just changes in potassium channels. We cannot expect that flupirtine and retigabine will achieve satisfactory results in their therapeutic application to treat fibromyalgia.


Text has been added to the section entitled Conclusion and perspectives highlighting that the complexity of the pathophysiology of fibromyalgia may limit the outcomes with these drugs.

3. Reference 21 and 52 was a repeat.

The reference section and citations have been revised for the double entry of an article.

Please find the revised manuscript as per the recommendations of the referees and editor.

Yours



Dr Kim Lawson

Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre
Sheffield Hallam University

Faculty of Health and Wellbeing, City Campus, Sheffield S1 1WB

Tel: +44 (0)114 225 3057

Fax: +44 (0)114 225 3066

Email: k.lawson@shu.ac.uk